Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era

BJU International

Volumn 106, Issue 1, 2010, Pages 37-43

  Isbarn, Hendrik ^a   Wanner, Manuela ^a   Salomon, Georg ^a   Steuber, Thomas ^a   Schlomm, Thorsten ^a   Köllermann, Jens ^a   Sauter, Guido ^a   Haese, Alexander ^a   Heinzer, Hans ^a   Huland, Hartwig ^a   Graefen, Markus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Biochemical recurrence; Cancer specific mortality; Overall survival; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BIOCHEMISTRY; CANCER CONTROL; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HORMONAL THERAPY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; EPIDEMIOLOGIC METHODS; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77953222605     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09134.x     Document Type: Article

References (20)

1. Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol 1997 15 : 331 335
2. Porter CR, Kodama K, Gibbons RP et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 2006 176 : 569 574
3. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993 20 : 713 725
4. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994 152 : 1850 1857
5. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 294 : 433 439
6. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004 172 : 910 914
7. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001 28 : 555 565
8. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002 167 : 528 534
9. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001 166 : 416 419
10. Desireddi NV, Roehl KA, Loeb S et al. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007 70 : 950 955
11. Gallina A, Chun FK, Suardi N et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 3 50 men treated with radical prostatectomy for prostate cancer. BJU Int 2008 101 : 1513 1518
12. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988 12 : 897 906
13. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974 111 : 58 64
14. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002 87 : 13 5
15. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982 128 : 492 497
16. Graefen M, Walz J, Huland H. Open retropubic nerve-sparing radical prostatectomy. Eur Urol 2006 49 : 38 48
17. Galvin DJ, Eastham JA. Critical appraisal of outcomes following open radical prostatectomy. Curr Opin Urol 2009 19 : 297 302
18. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005 352 : 1977 1984 (Pubitemid 40638368)
19. Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008 53 : 68 80
20. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006 Issue 4, CD006019